Seleziona la regione che meglio si adatta alla tua posizione o alle tue preferenze.
Questa impostazione controlla la lingua dell'interfaccia utente, inclusi i pulsanti, i menu e tutto il testo del sito. Seleziona la tua lingua preferita per la migliore esperienza di navigazione.
Seleziona le lingue per gli annunci di lavoro che desideri vedere. Questa impostazione determina quali annunci di lavoro ti verranno mostrati.
The blood-brain barrier (BBB) remains one of the greatest obstacles in modern medicine. While biological therapeutics such as antibodies, peptides, oligonucleotides, and viral vectors hold enormous promise for treating neurological disorders, their delivery to the brain is severely restricted by the BBB.
At the Laboratory for Therapeutic and Diagnostic Antibodies (KU Leuven), Prof. Maarten Dewilde and colleagues are developing next-generation technologies to transport biological therapeutics across the BBB. To strengthen our growing research program, we are seeking a highly motivated and ambitious PhD candidate to join our team and help advance innovative solutions for brain drug delivery. The candidate will gain hands-on experience in antibody and nanobody engineering, molecular cloning, protein expression and purification, viral vector technologies, cell-based BBB models, advanced imaging, and in vivo pharmacology.
KU Leuven is consistently ranked among Europe's leading universities and offers an international, collaborative, and multidisciplinary research environment.
You will join a multidisciplinary team of more than 15 researchers, including PhD students, postdoctoral scientists, technicians, and an innovation manager.
Our laboratory is a well-funded and expanding research group with a strong track record in antibody and nanobody engineering. We combine state-of-the-art infrastructure with multidisciplinary expertise to translate innovative concepts into therapeutic solutions with real clinical impact. The Laboratory for Therapeutic and Diagnostic Antibodies has a strong track record in translating innovative antibody technologies from concept to application, with active collaborations in academia and industry.
Our laboratory has developed a unique toolbox of nanobodies that exploit receptor-mediated transcytosis (RMT), a natural transport pathway used by nutrients to cross the BBB. By targeting transporters such as the transferrin receptor, CD98hc, insulin receptor, and glucose transporters, these nanobodies can act as molecular shuttles, enabling therapeutic cargo to move from the bloodstream into the brain.
Over the past decade, our team has generated and validated an extensive collection of nanobodies against both established and novel BBB transporters. Building on this expertise, we recently demonstrated proof-of-concept that these nanobody shuttles can also facilitate the transport of nanoparticles and viral vectors across the BBB.
This breakthrough opens exciting opportunities for the development of innovative therapies for neurological diseases and raises a broad range of fundamental, technological, and translational research questions. The successful candidate will work at the forefront of this emerging field, helping to establish next-generation strategies for delivering biological therapeutics, nanoparticles, and gene therapies to the brain.
As a PhD researcher, you will:
For more information please contact Prof. dr. Maarten Dewilde, mail: [email protected]. (Out of office August 1-22)
KU Leuven strives for an inclusive, respectful and socially safe environment. We embrace diversity among individuals and groups as an asset. Open dialogue and differences in perspective are essential for an ambitious research and educational environment. In our commitment to equal opportunity, we recognize the consequences of historical inequalities. We do not accept any form of discrimination based on, but not limited to, gender identity and expression, sexual orientation, age, ethnic or national background, skin colour, religious and philosophical diversity, neurodivergence, employment disability, health, or socioeconomic status. For questions about accessibility or support offered, we are happy to assist you at this email address.
KU Leuven is an autonomous university. It was founded in 1425. It was born of and has grown within the Catholic tradition.
Visita la pagina del datore di lavoro